<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928200</url>
  </required_header>
  <id_info>
    <org_study_id>T2006-002</org_study_id>
    <nct_id>NCT00928200</nct_id>
  </id_info>
  <brief_title>Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)</brief_title>
  <official_title>Intravenous Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia and Allergy to E. Coli Asparaginase (IND 104224)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutic Advances in Childhood Leukemia Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutic Advances in Childhood Leukemia Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study using the Erwinia form of asparaginase in place of the E. coli form
      using a standard re-induction regimen (Vincristine, Dexamethasone, Doxorubicin) for patients
      with relapsed ALL who have developed an allergy to the E. coli formulation. This study will
      administer the drug intravenously instead of the usual intramuscular route. The dose of
      Erwinia will be escalated in the absence of dose limiting toxicity. Patients must have first
      or second relapse ALL with a history of prior systemic reaction to E. coli asparaginase.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to lack of accrual.
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Each dose level is evaluated</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Relapsed Acute Lymphoblastic Leukemia</condition>
  <condition>Allergy to PEG e.Coli Asparaginase</condition>
  <condition>Allergy to Native e.Coli Asparaginase</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinase</intervention_name>
    <description>The dose of Erwinase will be assigned at study entry. Erwinase will be administered as a 2-hour intravenous infusion. A total of 10 doses will be given on a Monday-Wednesday-Friday schedule.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.5 mg/m2/dose IV push on days 1, 8, 15 and 22</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>10 mg/m2/day divided BID. Give by mouth days 1-14</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60 mg/m2/day IV over 15 minutes on day 1</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given Intrathecally to all patients with CNS negative disease at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple Intrathecal Therapy</intervention_name>
    <description>Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS positive at study entry. Doses determined by age.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated List of Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have relapsed or refractory acute lymphoblastic leukemia with a M3
             marrow (marrow blasts &gt;25%) who have had no more than two prior therapeutic attempts.

          -  Patients must have a history of prior systemic allergic reaction to E. coli
             asparaginase (native or pegylated), such as urticaria, wheezing, or anaphylaxis.

          -  Patients may be in first or second relapse and should not have received more than 2
             induction attempts.

          -  Patients must have less than 350mg/m2 lifetime exposure of anthracycline chemotherapy.

          -  Patients should not have received previous therapy using Erwinase.

        Exclusion Criteria:

          -  Patients with prior history of Grade 2 or greater asparaginase-induced symptomatic
             pancreatitis will be excluded.

          -  Patients with a prior history of asparaginase associated stroke are excluded.

          -  Patients will be excluded if their shortening fraction by echocardiogram is less than
             30%.

          -  Patients who are pregnant or nursing an infant.

        LABS

          -  Direct bilirubin &gt; 1.5x the institutional upper limit of normal for age. A total
             bilirubin result that is less than 1.5 times the institutional upper limit of normal
             for age may be used for eligibility if a direct bilirubin result is not available.

          -  SGPT (ALT) &gt; 4 x institutional upper limit of normal

          -  Amylase or Lipase &gt; 2 x institutional upper limit of normal

          -  Serum creatinine is &gt; the upper limit of normal for age at the institution's
             laboratory.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Grossman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hopital New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Gaynon, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Therapeutic Advances in Childhood Leukemia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakland Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital &amp; Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404-4597</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New York-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Kids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tacl.us</url>
    <description>For more information about this and other clinical trials, please visit the TACL website.</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>August 18, 2010</last_update_submitted>
  <last_update_submitted_qc>August 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Heather Grossman</name_title>
    <organization>Therapeutic Advances in Childhood Leukemia Consortium</organization>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Allergy</keyword>
  <keyword>Erwinia</keyword>
  <keyword>Acute</keyword>
  <keyword>Lymphoblastic</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

